Temozolomide wafer - Accurexa

Drug Profile

Temozolomide wafer - Accurexa

Alternative Names: ACX-31 - Accurexa; ACX-31 wafer - Accurexa

Latest Information Update: 16 Jan 2017

Price : $50

At a glance

  • Originator Accelerating Combination Therapies
  • Developer Accelerating Combination Therapies; Accurexa; DelMar Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Amides; Epoxy compounds; Ethylene glycols; Imidazoles; Small molecules; Triazenes
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Brain cancer
  • Research Solid tumours

Most Recent Events

  • 10 Jan 2017 Accurexa files for a new patent application related to the combination therapy of a PARP inhibitor and ACX 31
  • 07 Sep 2016 DelMar and Accurexa agree to co-develop ACX 31 alongwith dianhydrogalactitol for Cancer
  • 07 Sep 2016 Early research in Solid tumours in USA (Intracerebral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top